first blush line fy guidanc reiter howev closer look
reveal much mix pictur clear posit littl call
quiet concern hct-cm genesight reimburs overhang also surpris
genesight accrual revers wont help still believ risk/reward skew favor
updat littl elimin overhang
revenu line consensu expect gross margin
q/q bit better expect even notabl given
genesight accrual adjust higher mix lower-margin counsyl sale oper
spend expect non-oper item higher expect
off-set lower forecast tax rate ep line guidanc line
consensu expect exclud impact stock comp
hct revenu beat prenat counsyl revenu beat
pharma clinic servic revenu better
expect off-set genesight come see light forecast
combin prolari vectra endopredict also came light
first bad news genesight miss revenu expect note miss
attribut recent implement industry-wid laboratori benefit manag program
drove actual cash collect fall behind anticip level appear revenu
would otherwis line revenu reduct essenti
impact commerci payer calcul effect cut commerci asp
quarter messi good news revers calcul
last quarter mo thu go-forward quarterli impact commerci
seemingli asp seemingli improv
demonstr make progress vs document requir volum
grew demonstr concern novemb fda statement genet
test seemingli impact demand indic present genesight
data larg self-fund employ repres cover live
result updat reduc full year genesight revenu forecast
account accrual adjust impact asp move forward
continu assum broaden coverag could potenti materi upsid
point increment bad hct news call hct revenu actual
better expect said uncertainti linger possibl applic last
year ncd-ng germlin test potenti chang code
use bill consist heard other industri
belief ncd-ng appli germlin test ultim
get clear way neg compani like said
uncertainti linger also believ use/potenti use non-ng approach
afford protect regard potenti chang code myrisk seemingli
remain confid well posit also note hct account
rel small part total revenu cont page
pleas see page report import disclosur
p/fcf myriad valu little-to-no growth asset minimum
believ evolv lsd-msd revenu growth compani dd ep growth
believ even hereditari cancer test hct growth busi volum
offset price pressur genesight garner addit reimburs
product revenu growth includ pipelin counsyl come
per year aggreg beyond sourc upsid includ broader
reimburs genesight current cover almost sole counsyl synergi
 product specif half commerci payer cover genesight
ep estim could prove low function compani tad
aggressive/optimist targets/commun doubt go plan
said current valuat littl bake
genesight prolari reimbursement/
adopt major commerci payer
share stabil indic
expans within hereditari cancer
progress pipelin product
hct volum grow y/i
prolari volum grow
moder new coverag
decis nccn back
meaning revenu pipelin
decis major payer drive
materi inflect
hct revenu grow stronger
expect due expand indic
asp stabil
prolari revenu acceler major
commerci payer begin cover
pipelin product mypath
contribut revenu
hct volum asp declin due
competit pressur loss payer
due lack reimburs low
ldt regul increas cost
molecular diagnost lab offer test hereditari cancer
prostat cancer surgic decis reproduct health via recent acquisit
counsyl
hct better expect counsyl track ahead plan particularli
notabl given quarter potenti disrupt given stage integr
compani also effect tripl counsyl sale forc earli januari
increment benefit includ guidanc also margin pretti
good consid impact counsyl genesight accrual adjust guidanc
seem upward bia revenu line
fy revenu ep guidanc exclud stock comp
reiter guidanc line previou consensu note
decreas genesight revenu forecast also cut forecast prolari
vectra endopredict offset hct counsyl
pharma clinic servic
compani report thomson eikon cowen compani
cowen vs consensu mm except excl stock reiter exclud stock-bas compselect revenu metric mm except cancer vectra clinic y/i nmnmgrowth statement mm except per count forecast increas account counsyl spend organ sg also drop last quarter thought might high turn case ep expect exclud impact stock comp streetaccount consensu hct revenu ahead expect price describ stabl streetaccount consensu genesight came light expect major driver miss retroact adjust due accrual adjust relat lab benefit manag adjust genesight would expect demonstr impact document requir like lessen streetaccount consensu consensu model expect light forecast streetaccount consensu weaker expect streetaccount consensu beter expect essenti ecast counsyl revenu flat q/q adjust time highlight quarter come better expect streetaccount consensu revenu line expect compon gross margin declin q/q key driver accrual adjust flow complet gross margin line higher mix lower-margin counsyl revenu spend forecast cowen
compani report cowen compani
mm except cagrcommentstot reiter cancer molecular assum modest volum growth vs assum modest volum growth vs assum modest volum growth vs assum q/q growth vs adjust base prenat expect modest growth rel upsid sourc incl includ mypath melanomapharm clinic expect continu run rate sale delay growth cowen
compani report thomson eikon cowen compani
mm except per share datasep reiter research gener oper amort alreadi exclud adjust oper non-oper interest profit excl stock comp stock comp reiter stock comp oper tax rate reiter expect tax rate increas q/q earn per reiter exclud stock-bas compshar exclud stock share except per share datasep gross op genet consensu estim cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
risk downsid includ limit intens competit
expect greater expect share loss price eros less expect
contribut new product fda regul ldt
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock secur
cowen compani llc manag co-manag public offer past month
cowen compani llc receiv compens invest bank servic past month
past month client cowen compani llc cowen compani llc provid provid invest bank servic
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
avenu floor new york ny addit import disclosur except valuat method risk avail firm disclosur
websit http //cowen bluematrix com/sellside/disclosur action
equiti research price target cowen compani llc assign price target compani cover equiti research unless note otherwis equiti research price target
issuer stock repres valu analyst reason expect stock reach perform period twelv month price target equiti secur
report consid context prior publish cowen compani llc equiti research report includ disclosur equiti report
firm disclosur websit may may includ equiti research price target well develop relat issuer industri financi market
equiti research price target valuat methodolog risk associ achiev given equiti research price target pleas see analyst equiti research report
publish target
cowen cross-asset research due natur fix incom market issuer debt secur issuer discuss cowen cross-asset research report
assign rate price target may continu follow accordingli investor must regard brand report provid stand-alon analysi reflect
analyst opinion date report expect continu analysi addit report relat issuer debt secur issuer
time time cowen cross-asset research analyst provid invest recommend secur subject report recommend intend
time date public within paramet specifi individu report cowen cross-asset research invest recommend made
strictli case-by-cas basi recommend provid part overarch rate system set consist appli benchmark view express
cross-asset research report may differ view offer firm equiti research report prepar client
notic uk investor public produc cowen compani llc regul unit state finra commun person kind
describ articl servic market act promot order must transmit person without
notic european union investor individu produc recommend requir obtain certain licens financi regulatori author finra review
author current licens statu histori employ histori report regulatori custom disput crimin matter via brokercheck finra http //
brokercheck finra org/ individu licens statu finra constru endors finra gener biograph inform also avail
research analyst www cowen com
addit complet preced recommend histori relat recommend research report avail http //cowen bluematrix com/sellside/
recommend contain report produc februari et dissemin februari et
copyright user agreement gener inform relat report
cowen compani llc right reserv member nyse finra sipc research report prepar exclus use cowen client may
reproduc display modifi distribut transmit disclos whole part form manner other outsid organ without express prior
written consent cowen cowen research report distribut simultan client elig receiv research report unauthor use disclosur
